BioWorld

Jan. 3, 2006

View Archived Issues

Genentech Submits Lucentis BLA For Age-Related AMD

Ever on the march, Genentech Inc. rounded out the year with another regulatory move, submitting - as promised - a biologics license application for Lucentis against neovascular wet age-related macular degeneration. (BioWorld Today) Read More

Vanda Seeking $75M IPO For CNS Drug Development

Read More

Study Finds Possibly Better Approach To Cox-2 Inhibition

Read More

Lawyers Do Not Expect New Curbs On Drug Advertising

Read More

Holiday Notice

Read More

Other News To Note

Read More